Neurofibromatosis Type 2 Clinical Trial
Official title:
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05521048 -
Doxycycline in Cutaneous Schwannoma (NF2)
|
Phase 1/Phase 2 | |
| Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
| Completed |
NCT01767792 -
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Recruiting |
NCT05130866 -
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
| Completed |
NCT01125046 -
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
|
Phase 2 | |
| Completed |
NCT03210285 -
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
|
||
| Completed |
NCT02934256 -
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Terminated |
NCT01345136 -
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
|
Phase 2 | |
| Completed |
NCT02104323 -
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Completed |
NCT02246231 -
Effect of Implant Position on Magnetic Resonance Image Distortion
|
N/A | |
| Terminated |
NCT02282917 -
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
|
Early Phase 1 | |
| Completed |
NCT02129647 -
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
| No longer available |
NCT02589912 -
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
|